LNTH holds a negative net debt to ebitda ratio, with a forward p/e ratio around 16. Revenue growth was up over 18% for the TTM, and operating margin was around 40% compared to ~15% for healthcare companies in the drug manufacturing industry.Technically, there is a potential wedge forming, though I can see a breakout bounce off of the .382 fib coming too. Strength showing relative to the S&P.
Note
Forgot to mention: I'm planning on entering on confirmation of EMA support
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.